Human Recombinant B7-2 (from HEK293)
Marketsource
Supplier: ACRO Biosystems
About this item
2 Options Available Below
- Item requires temperature control for storage and delivery with additional fees. It's not eligible for return due to safety and quality concerns. Consider requirements before purchasing.
- Return Policy
Product Details & Documents
Specifications for Product Family
Specifications
Specifications
- Catalog No:
- 103738-844
- 103738-842
- Protein/Peptide Name:
- B7-2
- B7-2
- Protein Synonyms:
- B70|CD86|CD28LG2|LAB72|B7-2|MGC34413
- B70|CD86|CD28LG2|LAB72|B7-2|MGC34413
- Protein/Peptide Type:
- Recombinant
- Recombinant
- Species:
- Human
- Human
- Source:
- HEK293 cells
- HEK293 cells
- Gene ID:
- P42081
- P42081
- Protease-free:
- Y
- Y
- Animal-Free:
- Y
- Y
- Nuclease-free:
- Y
- Y
- Carrier-Free:
- Y
- Y
- Endotoxin Level:
- Low
- Low
- Endotoxin Content:
- Less than 1.0 EU per μg by the LAL method.
- Less than 1.0 EU per μg by the LAL method.
- Biological Activity:
- Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.; Measured by its binding ability in a functional ELISA. Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) with a linear range of 19-156 ng/mL (QC tested).; Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested). ; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 μg/mL (Routinely tested).; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 μg /mL. The IC50 is 1.014 μg/mL (Routinely tested).
- Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.; Measured by its binding ability in a functional ELISA. Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) with a linear range of 19-156 ng/mL (QC tested).; Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested). ; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 μg/mL (Routinely tested).; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 μg /mL. The IC50 is 1.014 μg/mL (Routinely tested).
- Purity:
- >95%
- >95%
- Formulation:
- Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
- Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
- Molecular Weight:
- 53.8 kDa
- 53.8 kDa
- Storage Conditions:
- –20 °C
- –20 °C
- Shipping Temperature:
- Powder,RT
- Powder,RT
Specifications
Product Family Options
Product Information
- SizeAvailabilityPrice
- Supplier Number: CD6H82F525UGItem requires temperature control for storage and delivery with additional fees. It's not eligible for return due to safety and quality concerns. Consider requirements before purchasing.Specifications:Marketsource
More
Specifications
Cat. No.103738-844Protein/Peptide NameB7-2Protein SynonymsB70|CD86|CD28LG2|LAB72|B7-2|MGC34413Protein/Peptide TypeRecombinantSpeciesHumanSourceHEK293 cellsGene IDP42081Protease-freeYAnimal-FreeYNuclease-freeYCarrier-FreeYEndotoxin LevelLowEndotoxin ContentLess than 1.0 EU per μg by the LAL method.Biological ActivityLyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.; Measured by its binding ability in a functional ELISA. Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) with a linear range of 19-156 ng/mL (QC tested).; Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested). ; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 μg/mL (Routinely tested).; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 μg /mL. The IC50 is 1.014 μg/mL (Routinely tested).Purity>95%FormulationLyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.Molecular Weight53.8 kDaStorage Conditions–20 °CShipping TemperaturePowder,RTMarketsource - Supplier Number: CD6H82F5200UGItem requires temperature control for storage and delivery with additional fees. It's not eligible for return due to safety and quality concerns. Consider requirements before purchasing.Specifications:Marketsource
More
Specifications
Cat. No.103738-842Protein/Peptide NameB7-2Protein SynonymsB70|CD86|CD28LG2|LAB72|B7-2|MGC34413Protein/Peptide TypeRecombinantSpeciesHumanSourceHEK293 cellsGene IDP42081Protease-freeYAnimal-FreeYNuclease-freeYCarrier-FreeYEndotoxin LevelLowEndotoxin ContentLess than 1.0 EU per μg by the LAL method.Biological ActivityLyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.; Measured by its binding ability in a functional ELISA. Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) with a linear range of 19-156 ng/mL (QC tested).; Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) binding reactions. The half maximal inhibitory concentration (IC50) is 0.1701 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested). ; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).; Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-2 is 2 μg/mL (Routinely tested).; FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-2 is 2 μg /mL. The IC50 is 1.014 μg/mL (Routinely tested).Purity>95%FormulationLyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.Molecular Weight53.8 kDaStorage Conditions–20 °CShipping TemperaturePowder,RTMarketsource
Recommendations
Recommendations will be personalized based on your shopping preferences only if you have given your consent by enabling "Enhance my Shopping Experience" on the "Personal Info page".
Otherwise, you will receive generic recommendations.